Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer

Yu Chieh Lee, Chii Hong Lee, Hsiang Ping Tsai, Herng Wei An, Chi-Ming Lee, Jen Chine Wu, Chien Shu Chen, Shih Hao Huang, Jaulang Hwang, Kur Ta Cheng, Phui Ly Leiw, Chi Long Chen, Chun Mao Lin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

DNA topoisomerase I (TOP1) levels of several human neoplasms are higher than those of normal tissues. TOP1 inhibitors are widely used in treating conventional therapy-resistant ovarian cancers. However, patients may develop resistance to TOP1 inhibitors, hampering chemotherapy success. In this study, we examined the mechanisms associated with the development of camptothecin (CPT) resistance in ovarian cancers and identified evodiamine (EVO), a natural product with TOP1 inhibiting activity that overcomes the resistance. The correlations among TOP1 levels, cancer staging, and overall survival (OS) were analyzed. The effect of EVO on CPT-resistant ovarian cancer was evaluated in vitro and in vivo. TOP1 was associated with poor prognosis in ovarian cancers (p = 0.024). EVO induced apoptosis that was detected using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The tumor size decreased significantly in the EVO treatment group compared with the control group (p <0.01) in a xenograft mouse model. Effects of drugs targeting TOP1 for prognosis and therapy in CPT-resistant ovarian cancer are anticipated. EVO with TOP1 can be developed as an antiproliferative agent for overcoming CPT resistance in ovarian cancers.

Original languageEnglish
Article numbere0132579
JournalPLoS One
Volume10
Issue number7
DOIs
Publication statusPublished - Jul 24 2015

Fingerprint

DNA topoisomerase
Camptothecin
Type I DNA Topoisomerase
ovarian neoplasms
Ovarian Neoplasms
prognosis
therapeutics
neoplasms
Therapeutics
Chemotherapy
DNA Nucleotidylexotransferase
Flow cytometry
Biological Products
Heterografts
Neoplasm Staging
Labeling
Drug Delivery Systems
Tumors
Assays
transferases

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer. / Lee, Yu Chieh; Lee, Chii Hong; Tsai, Hsiang Ping; An, Herng Wei; Lee, Chi-Ming; Wu, Jen Chine; Chen, Chien Shu; Huang, Shih Hao; Hwang, Jaulang; Cheng, Kur Ta; Leiw, Phui Ly; Chen, Chi Long; Lin, Chun Mao.

In: PLoS One, Vol. 10, No. 7, e0132579, 24.07.2015.

Research output: Contribution to journalArticle

Lee, YC, Lee, CH, Tsai, HP, An, HW, Lee, C-M, Wu, JC, Chen, CS, Huang, SH, Hwang, J, Cheng, KT, Leiw, PL, Chen, CL & Lin, CM 2015, 'Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer', PLoS One, vol. 10, no. 7, e0132579. https://doi.org/10.1371/journal.pone.0132579
Lee, Yu Chieh ; Lee, Chii Hong ; Tsai, Hsiang Ping ; An, Herng Wei ; Lee, Chi-Ming ; Wu, Jen Chine ; Chen, Chien Shu ; Huang, Shih Hao ; Hwang, Jaulang ; Cheng, Kur Ta ; Leiw, Phui Ly ; Chen, Chi Long ; Lin, Chun Mao. / Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer. In: PLoS One. 2015 ; Vol. 10, No. 7.
@article{4123e794ca8a4ce49b094458d7740e9b,
title = "Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer",
abstract = "DNA topoisomerase I (TOP1) levels of several human neoplasms are higher than those of normal tissues. TOP1 inhibitors are widely used in treating conventional therapy-resistant ovarian cancers. However, patients may develop resistance to TOP1 inhibitors, hampering chemotherapy success. In this study, we examined the mechanisms associated with the development of camptothecin (CPT) resistance in ovarian cancers and identified evodiamine (EVO), a natural product with TOP1 inhibiting activity that overcomes the resistance. The correlations among TOP1 levels, cancer staging, and overall survival (OS) were analyzed. The effect of EVO on CPT-resistant ovarian cancer was evaluated in vitro and in vivo. TOP1 was associated with poor prognosis in ovarian cancers (p = 0.024). EVO induced apoptosis that was detected using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The tumor size decreased significantly in the EVO treatment group compared with the control group (p <0.01) in a xenograft mouse model. Effects of drugs targeting TOP1 for prognosis and therapy in CPT-resistant ovarian cancer are anticipated. EVO with TOP1 can be developed as an antiproliferative agent for overcoming CPT resistance in ovarian cancers.",
author = "Lee, {Yu Chieh} and Lee, {Chii Hong} and Tsai, {Hsiang Ping} and An, {Herng Wei} and Chi-Ming Lee and Wu, {Jen Chine} and Chen, {Chien Shu} and Huang, {Shih Hao} and Jaulang Hwang and Cheng, {Kur Ta} and Leiw, {Phui Ly} and Chen, {Chi Long} and Lin, {Chun Mao}",
year = "2015",
month = "7",
day = "24",
doi = "10.1371/journal.pone.0132579",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer

AU - Lee, Yu Chieh

AU - Lee, Chii Hong

AU - Tsai, Hsiang Ping

AU - An, Herng Wei

AU - Lee, Chi-Ming

AU - Wu, Jen Chine

AU - Chen, Chien Shu

AU - Huang, Shih Hao

AU - Hwang, Jaulang

AU - Cheng, Kur Ta

AU - Leiw, Phui Ly

AU - Chen, Chi Long

AU - Lin, Chun Mao

PY - 2015/7/24

Y1 - 2015/7/24

N2 - DNA topoisomerase I (TOP1) levels of several human neoplasms are higher than those of normal tissues. TOP1 inhibitors are widely used in treating conventional therapy-resistant ovarian cancers. However, patients may develop resistance to TOP1 inhibitors, hampering chemotherapy success. In this study, we examined the mechanisms associated with the development of camptothecin (CPT) resistance in ovarian cancers and identified evodiamine (EVO), a natural product with TOP1 inhibiting activity that overcomes the resistance. The correlations among TOP1 levels, cancer staging, and overall survival (OS) were analyzed. The effect of EVO on CPT-resistant ovarian cancer was evaluated in vitro and in vivo. TOP1 was associated with poor prognosis in ovarian cancers (p = 0.024). EVO induced apoptosis that was detected using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The tumor size decreased significantly in the EVO treatment group compared with the control group (p <0.01) in a xenograft mouse model. Effects of drugs targeting TOP1 for prognosis and therapy in CPT-resistant ovarian cancer are anticipated. EVO with TOP1 can be developed as an antiproliferative agent for overcoming CPT resistance in ovarian cancers.

AB - DNA topoisomerase I (TOP1) levels of several human neoplasms are higher than those of normal tissues. TOP1 inhibitors are widely used in treating conventional therapy-resistant ovarian cancers. However, patients may develop resistance to TOP1 inhibitors, hampering chemotherapy success. In this study, we examined the mechanisms associated with the development of camptothecin (CPT) resistance in ovarian cancers and identified evodiamine (EVO), a natural product with TOP1 inhibiting activity that overcomes the resistance. The correlations among TOP1 levels, cancer staging, and overall survival (OS) were analyzed. The effect of EVO on CPT-resistant ovarian cancer was evaluated in vitro and in vivo. TOP1 was associated with poor prognosis in ovarian cancers (p = 0.024). EVO induced apoptosis that was detected using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The tumor size decreased significantly in the EVO treatment group compared with the control group (p <0.01) in a xenograft mouse model. Effects of drugs targeting TOP1 for prognosis and therapy in CPT-resistant ovarian cancer are anticipated. EVO with TOP1 can be developed as an antiproliferative agent for overcoming CPT resistance in ovarian cancers.

UR - http://www.scopus.com/inward/record.url?scp=84942060624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942060624&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0132579

DO - 10.1371/journal.pone.0132579

M3 - Article

C2 - 26207989

AN - SCOPUS:84942060624

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0132579

ER -